Topics: Personality Disorders

Are you diagnosing a personality disorder (PD) in half of your patients? If not, you probably are not asking enough questions.

Topics: Personality Disorders

Most authorities in the world of borderline personality disorder (BPD) say that psychotherapy is the mainstay of treatment and that medications should only be used adjunctively to treat symptoms as they arise. Nevertheless, medications are used relatively frequently for this disorder.

Topics: Personality Disorders

This split between Axis I and II came about in 1980 with the publication of DSM-III. It came out of a concern that disorders like personality disorders, learning disorders, mental retardation and autism could be overlooked because other, more florid disorders would take everyone’s attention.

Topics: Anxiety Disorder

Cephalon’s selective GABA reuptake inhibitor, the antiepileptic drug tiagabine (Gabitril), was assessed for the treatment of generalized anxiety disorder in adults in three large 10-week placebo-controlled studies.

Topics: Antipsychotics

The FDA issued a Not Approvable letter regarding Vanda Pharmaceutical’s antipsychotic medication iloperidone (Fanapta). The agency based its decision on iloperidone’s question able efficacy results versus risperidone.

Topics: Antidepressants

Based on data from eight randomized double-blind, placebo-controlled trials, researchers found that 79% of patients who responded to placebo in the initial phase of the trial maintained their response while continuing to take placebo during the continuation phase of the trial.

An intensive two-year-long early intervention for first episode psychosis showed early promise relative to standard care, yielding superior improvement in both positive and negative symptoms, as well as lower rates of substance abuse and lower antipsychotic medication doses.